| Filed On | Filing |
|---|---|
| 30 Oct 2026 |
8-K: Regulation FD Disclosure
This exhibit provides certain supplemental non-GAAP financial measures for the quarter ended September 30, 2026. As disclosed in the accompanying Current Report on Form 8-K, Organon & Co. (the “Company”) is furnishing this information in... |
| 31 Jul 2026 |
8-K: Regulation FD Disclosure
This exhibit provides certain supplemental non-GAAP financial measures for the quarter ended June 30, 2026. As disclosed in the accompanying Current Report on Form 8-K, Organon & Co. (the “Company”) is furnishing this information in lieu... |
| 23 Jul 2026 |
8-K: Submission of Matters to a Vote of Security Holders
A special meeting of stockholders (the “Special Meeting”) of Organon & Co., a Delaware corporation (the “Company”), was held on July 23, 2026 at 10:00 a.m., Eastern Time, via a virtual meeting website. The Special Meeting was held in ord... |
| 17 Jul 2026 |
8-K: Other Events
As previously disclosed, on April 26, 2026, Organon & Co., a Delaware corporation (the “Company”), entered into an Agreement and Plan of Merger (the “Merger Agreement”) by and among the Company, Sun Pharmaceutical Holdings USA, Inc. (“Su... |
| 11 Jun 2026 |
8-K: Departure/Election of Directors or Officers; Compensation; Submission of Matters to a Vote of Security Holders
Departure of Directors or Certain Officers; Election of Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. |
| 30 Apr 2026 |
8-K: Results of Operations and Financial Condition
First quarter 2026 revenue of $1.460 billion, down 4% as-reported and down 9% excluding the impact of foreign currency. |
| 27 Apr 2026 |
8-K: Entry into a Material Definitive Agreement; Departure/Election of Directors or Officers; Compensation +1 more
Exhibit A Form of Certificate of Incorporation of the Surviving Corporation |
| 20 Feb 2026 |
8-K: Other Events
As previously disclosed on February 12, 2026, the Audit Committee of the Board of Directors of Organon & Co. (the “Company”) conducted an independent review of the information brought to the Audit Committee’s attention on February 11, 20... |
| 12 Feb 2026 |
8-K: Results of Operations and Financial Condition; Regulation FD Disclosure
Full year 2025 revenue of $6.2 billion, down 3% on both an as-reported basis and at constant currency |
| 10 Nov 2025 |
8-K: Results of Operations and Financial Condition; Regulation FD Disclosure
Third quarter 2025 revenue of $1.602 billion, up 1% as-reported and down 1% excluding the impact of foreign currency |
| 07 Nov 2025 |
8-K: Departure/Election of Directors or Officers; Compensation
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. |
| 27 Oct 2025 |
8-K: Departure/Election of Directors or Officers; Compensation; Other Events
Organon Appoints Company Executive Joseph Morrissey as Interim CEO and Board Chair Carrie Cox as Executive Chair; Announces Results of Audit Committee Investigation |
| 05 Aug 2025 |
8-K: Results of Operations and Financial Condition; Regulation FD Disclosure
Second quarter 2025 diluted earnings per share of $0.56 and non-GAAP Adjusted diluted earnings per share of $1.00; GAAP diluted earnings per share includes a $46 million gain, or $0.14 per share, for early extinguishment of debt |
| 12 Jun 2025 |
8-K: Departure/Election of Directors or Officers; Compensation; Submission of Matters to a Vote of Security Holders
Departure of Directors or Certain Officers; Election of Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. |
| 27 May 2025 |
8-K: Other Events
US Food and Drug Administration (FDA) Grants Interchangeability Designation to Samsung Bioepis and Organon HADLIMA™ (adalimumab-bwwd) Injection |
| 01 May 2025 |
8-K: Results of Operations and Financial Condition; Regulation FD Disclosure +1 more
Company affirms full year 2025 financial guidance, resets dividend payout to strengthen capital structure |
| 15 Apr 2025 |
8-K: Departure/Election of Directors or Officers; Compensation; Regulation FD Disclosure
JERSEY CITY, N.J.-- (BUSINESS WIRE) -- April 15, 2025 -- Organon (NYSE: OGN) a global healthcare company with a focus on women’s health, today announced the appointment of Ramona A. Sequeira, President of the Global Portfolio Division at... |
| 13 Feb 2025 |
8-K: Results of Operations and Financial Condition; Regulation FD Disclosure
Full year 2024 revenue of $6.4 billion, up 2% as-reported and 3% at constant currency |
| 21 Jan 2025 |
8-K: Departure/Election of Directors or Officers; Compensation
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. |
| 23 Dec 2024 |
8-K: Other Events
On December 20, 2024, following the previously-announced resignation of Martha E. McGarry from the Board of Directors (the “Board”) of Organon & Co., the Board reduced its size to eleven members, which eliminated the vacancy created by M... |
Loading...